MarketPulse

aneurysmal subarachnoid hemorrhage

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Grace Therapeutics' GTx-104 Meets Primary Endpoint in Pivotal aSAH Trial

Grace Therapeutics reports STRIVE-ON Phase 3 trial success for GTx-104, reducing hypotension and improving outcomes in aneurysmal subarachnoid hemorrhage patients versus oral nimodipine.
GRCEclinical trial resultsGTx-104
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Grace Therapeutics to Present at TD Cowen Conference; FDA Sets GTx-104 Review Date

Grace Therapeutics will present at TD Cowen conference in March 2026. FDA sets April 2026 review date for GTx-104 aneurysmal subarachnoid hemorrhage treatment.
GRCEFDA approvalclinical-stage